๐ Risk-adapted Treatment Strategy For COVID-19 Patients.
BACKGROUND: There are no clear expert consensus or guidelines on how to treat 2019 coronavirus disease (COVID-19). The objective of this study is to investigate the short-term effect of risk-adapted treatment strategy on patients with COVID-19. METHODS: We collected the medical records of 55 COVID-19 patients for analysis. We divided these patients into mild, moderate and severe groups, and risk-adapted treatment approaches were given according to the illness severity. RESULTS: Twelve patients were in mild group and 22 were in moderate group (non-severe group, n=34), and 21 patients were in severe group. At the end of the first two weeks after admission, clinical manifestations had completely despeared in 31(91.2%)patients in non-severe group, and 18(85.7%) patients in severe group (p=0.85). Both groups had a satisfied chest CT imaging recovery, which includes 22(64.7%) patients in non-severe group and 12(57.1%) patients in severe group recovered at least 50% of the whole leisions in the first week, and 28(82.4%) and 16(76.2%) recovered at least 75% in the second week, respectively. There were no significant differences in SARS-CoV-2 RNA clearance between two group (p=0.92). There were also no significant differences in the levels of SARS-CoV-2-IgM and IgG antibody production between the two groups (p=0.13, 0.62). There were 45 cases were discharged from the hospital, and no patients died at the time of this clinical analysis. CONCLUSIONS: Risk-adapted treatment strategy was associated with significant clinical manifestations alleviation and clinical imaging recovery. In severe COVID-19 patients, early and short-term use of low-dose methylprednisolone was beneficial and did not delay SARS-CoV-2 RNA clearance and influence IgG antibody production.
keywords
๐ COVID-19 (1240)
๐ antiviral treatment (34)
๐ low-dose corticosteroid (1)
๐ novel coronavirus pneumonia (61)
๐ risk-adapted treatment strategy (1)
๐ significant differences (40)
author
๐ค Zheng, Changcheng
๐ค Wang, Jinquan
๐ค Guo, Hui
๐ค Lu, Zhaohui
๐ค Ma, Yan
๐ค Zhu, Yuyou
๐ค Xia, Daqing
๐ค Wang, Yinzhong
๐ค He, Hongliang
๐ค Zhou, Jian
๐ค Wang, Yong
๐ค Fei, Mingming
๐ค Yin, Yihong
๐ค Zheng, Mao
๐ค Xu, Yehong
year
โฐ 2020
journal
๐ Int J Infect Dis
issn
๐
volume
number
page
citedbycount
0
download
๐ [BibTeX]